Status:

COMPLETED

Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo

Lead Sponsor:

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Conditions:

VITILIGO

Eligibility:

All Genders

18-65 years

Brief Summary

This study aims to evaluate some differences in the immune system between patients with vitiligo and patients without the disease. These differences will be evaluated by the extraction of peripheral ...

Eligibility Criteria

Inclusion

  • \- Patient with vitiligo without treatment

Exclusion

  • Patient with inmunosupressive disease
  • Patient receiving vitiligo treatment

Key Trial Info

Start Date :

October 27 2015

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 13 2016

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT03249064

Start Date

October 27 2015

End Date

September 13 2016

Last Update

August 22 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital de la Santa Creu i Sant Pau

Barcelona, Spain, 08025

Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo | DecenTrialz